FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org September 21, 2007 (10.1056/NEJMoa075392)

	Full Text PDF Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited.

Methods In an open-label, controlled, multicenter trial, we randomly assigned 708 patients with a suboptimal glycated hemoglobin level (7.0 to 10.0%) who were receiving maximally tolerated doses of metformin and sulfonylurea to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Outcome measures at 1 year were the mean glycated hemoglobin level, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain.

Results At 1 year, mean glycated hemoglobin levels were similar in the biphasic group (7.3%) and the prandial group (7.2%) (P=0.08) but higher in the basal group (7.6%, P<0.001 for both comparisons). The respective proportions of patients with a glycated hemoglobin level of 6.5% or less were 17.0%, 23.9%, and 8.1%; respective mean numbers of hypoglycemic events per patient per year were 5.7, 12.0, and 2.3; and respective mean weight gains were 4.7 kg, 5.7 kg, and 1.9 kg. Rates of adverse events were similar among the three groups.

Conclusions A single analogue-insulin formulation added to metformin and sulfonylurea resulted in a glycated hemoglobin level of 6.5% or less in a minority of patients at 1 year. The addition of biphasic or prandial insulin aspart reduced levels more than the addition of basal insulin detemir but were associated with greater risks of hypoglycemia and weight gain. (Current Controlled Trials number, ISRCTN51125379 [controlled-trials.com] .)

Source Information

From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism (R.R.H., K.I.T., A.J.F., J.F.K., S.P., J.C.L.) and the Department of Primary Health Care (A.J.F.), University of Oxford, Oxford; and the Department of Cardiovascular Sciences, University of Leicester, Leicester (M.J.D.) — all in the United Kingdom.

This article (10.1056/NEJMoa075392) was published at www.nejm.org on September 21, 2007. It will appear in the October 25 issue of the Journal.

Address reprint requests to Dr. Holman at the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom, or at rury.holman{at}dtu.ox.ac.uk.

Full Text of this Article

This article has been cited by other articles:

• Lund, S. S, Tarnow, L., Frandsen, M., Nielsen, B. B, Hansen, B. V, Pedersen, O., Parving, H.-H., Vaag, A. A (2009). Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 339: b4324-b4324 [Abstract] [Full Text]  
• Swinnen, S. G., Hoekstra, J. B., DeVries, J. H. (2009). Insulin Therapy for Type 2 Diabetes. Diabetes Care 32: S253-S259 [Full Text]  
• Bretzel, R. G., Eckhard, M., Landgraf, W., Owens, D. R., Linn, T. (2009). Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32: S260-S265 [Full Text]  
• Meneghini, L. F. (2009). Early Insulin Treatment in Type 2 Diabetes: What are the pros?. Diabetes Care 32: S266-S269 [Full Text]  
• Heller, S. R., on behalf of the ADVANCE Collaborative Group, (2009). A Summary of the ADVANCE Trial. Diabetes Care 32: S357-S361 [Full Text]  
• Roden, M. (2009). Optimal Insulin Treatment in Type 2 Diabetes. NEJM 361: 1801-1803 [Full Text]  
• Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., Paul, S. K., the 4-T Study Group, (2009). Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. NEJM 361: 1736-1747 [Abstract] [Full Text]  
• Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., Porter, L. (2009). Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Diabetes Care 32: 1577-1582 [Abstract] [Full Text]  
• Wilding, J. P.H., Norwood, P., T'joen, C., Bastien, A., List, J. F., Fiedorek, F. T. (2009). A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656-1662 [Abstract] [Full Text]  
• McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., Herman, W. H. (2009). Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD). Diabetes Care 32: 971-976 [Abstract] [Full Text]  
• Buse, J. B., Wolffenbuttel, B. H.R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., Martin, S. A. (2009). DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 32: 1007-1013 [Abstract] [Full Text]  
• Crasto, W, Jarvis, J, Khunti, K, Davies, M J (2009). New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad. Med. J. 85: 257-267 [Abstract] [Full Text]  
• DeFronzo, R. A. (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 58: 773-795 [Full Text]  
• Henske, J. A., Griffith, M. L., Fowler, M. J. (2009). Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Clin. Diabetes 27: 72-76 [Full Text]  
• Freeman, J. S. (2009). Insulin Analog Therapy: Improving the Match With Physiologic Insulin Secretion. JAOA: Journal of the American Osteopathic Association 109: 26-36 [Abstract] [Full Text]  
• Rosenstock, J., Bergenstal, R., DeFronzo, R. A., Hirsch, I. B., Klonoff, D., Boss, A. H., Kramer, D., Petrucci, R., Yu, W., Levy, B., for the 0008 Study Group, (2008). Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents. Diabetes Care 31: 2177-2182 [Abstract] [Full Text]  
• Esposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., Giugliano, D. (2008). Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control: A Randomized Trial. ANN INTERN MED 149: 531-539 [Abstract] [Full Text]  
• Qayyum, R., Bolen, S., Maruthur, N., Feldman, L., Wilson, L. M., Marinopoulos, S. S., Ranasinghe, P., Amer, M., Bass, E. B. (2008). Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes. ANN INTERN MED 149: 549-559 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Approaches to Treatment of Type 2 Diabetes. Diabetes Care 31: 1697-1703 [Full Text]  
• Ubogagu, E., Samarasinghe, Y., Munro, N., Feher, M. D (2008). Switching basal analogue insulins -- short-term weight effects. British Journal of Diabetes & Vascular Disease 8: 183-186 [Abstract]  
• Davis, N. J., Wylie-Rosett, J. (2008). Death to Carbohydrate Counting?. Diabetes Care 31: 1467-1468 [Full Text]  
• Dokken, B. B. (2008). The Parodox of Glycemic Control and Cardiovascular Complications: Sorting Out the Data. Diabetes Spectr. 21: 150-152 [Full Text]  
• Atkin, S., Walton, C. (2008). Commentary: controversies in NICE guidance on management of type 2 diabetes. BMJ 336: 1308-1309 [Full Text]  
• Pignone, M. (2008). Choosing an Insulin Regimen for Patients With Type 2 Diabetes. Clin. Diabetes 26: 63-64 [Full Text]  
• Dagdelen, S., Ilag, L. L., Martin, S., Jacober, S. J., Holman, R. R., Farmer, A. J., Davies, M. J., McMahon, G. T., Dluhy, R. G. (2008). Addition of Insulin to Oral Therapy in Type 2 Diabetes. NEJM 358: 1197-1198 [Full Text]  
• Home, P. (2008). Safety of very tight blood glucose control in type 2 diabetes. BMJ 336: 458-459 [Full Text]  
• Riddle, M. C. (2008). Starting and Advancing Insulin for Type 2 Diabetes: Algorithms and Individualized Methods Are Both Necessary. J. Clin. Endocrinol. Metab. 93: 372-374 [Full Text]  
• McMahon, G. T., Dluhy, R. G. (2007). Intention to Treat -- Initiating Insulin and the 4-T Study. NEJM 357: 1759-1761 [Full Text]  
• (2007). Initiating Insulin in Type 2 Diabetes The "4-T" Trial. JWatch General 2007: 1-1 [Full Text]